EMED
Electromedical Technologies, Inc.0.0002
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
746.46KP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Electromedical Technologies posted Q3 net sales of $42.5k, down 87% y/y from $323.6k as it winds down current product sales for the new Wellness Pro Infinity, while YTD sales fell 43% y/y to $570.4k with gross margin dipping to 72% from 78%. Operating loss widened to $381k from $239k y/y on lower volume, yet net loss grew to $725k versus $377k, driven by $339k change in fair value of derivative liabilities. Customer deposits surged to $764k from $197k on Infinity pre-orders. Cash dwindled to $35k amid $80k YTD operating burn; $1.4M convertible notes (12% cap post-settlement to Sep 2025) and $150k government debt loom, with one $93k note in default. Shares outstanding ballooned to 725M. Customer concentration risks persist.
10-Q
Q2 FY2024 results
Electromedical Technologies posted Q2 net sales of $237.6K, down 19% y/y yet with gross margin steady at 73% amid product wind-down for the new Wellness Pro Infinity; SG&A plunged 26% y/y to $425.1K on lower payroll and travel, trimming operating loss to $251.8K from $341.4K. Other income of $483.1K—driven by $82K reversed default penalties from convertible note settlements—flipped operations to $231.2K net income, versus $1.5M loss last year; QTD cash burn eased to $49.4K from operations, with $116.9K cash and $1.5M notes (one $105.5K in default). Customer A drove 46.9% of sales. Settlements extended maturities to Sep 2025, capped rates at 12%. Diluted shares exploded to 1.94B on conversions, muting $0.00 EPS. Debt defaults loom large.
8-K
Authorized shares tripled
10-Q
Q1 FY2024 results
Electromedical Technologies posted Q1 revenue of $290K, down 23% y/y from $379K yet holding a solid 75% gross margin versus 77% last year, as sales wind down ahead of the new Wellness Pro Infinity. SG&A plunged 76% to $372K, trimming the operating loss to $155K from $1.3M, but derivative fair value changes and interest drove net loss wider to $836K from $456K. Cash dipped to $79K amid $158K operating burn, offset by $150K new convertible notes; total debt sits at $1.6M principal with $1.4M derivatives, while settlements extended maturities to Sep 2025 and capped rates at 12%. Customer A took 35% of sales. Debt defaults linger.
8-K
Auditor switch disclosed
Electromedical Technologies dismissed dbbmckennon as its auditor on May 17, 2024, after the firm declined reelection; prior reports flagged going concern risks from recurring losses and working capital deficits, but no disagreements arose. The board promptly engaged Hudgens CPA as replacement, with no prior consultations. Clean transition. dbbmckennon letter filed as Exhibit 16.1.
AMIX
Autonomix Medical, Inc.
0.63-0.03
BWAY
Brainsway Ltd.
16.87-0.47
DYNT
Dynatronics Corp.
0.04+0.00
EBRCZ
EBR SYSTEMS INC NPV CDI 1:1
0.60+0.00
ECOR
electroCore, Inc.
4.79+0.02
ELMD
Electromed, Inc.
29.88+0.28
HSDT
Solana Company
3.10+0.06
NMTC
NeuroOne Medical Technologies C
0.71+0.05
STME
Stimcell Energetics, Inc.
0.37-0.04
TCMD
Tactile Systems Technology, Inc
28.95+0.52